Lack of dimer formation ability in rat strains with low aldehyde oxidase activity

Xenobiotica

Volumn 37, Issue 7, 2007, Pages 709-716

  Itoh, K ^a   Maruyama, H ^a   Adachi, M ^a   Hoshino, K ^a   Watanabe, N ^b   Tanaka, Y ^a  

^a TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

Aldehyde oxidase; Native PAGE; Rat strain difference; Western blot

Indexed keywords

4 (4 CYANOANILINO) 6,7 DIHYDRO 7 HYDROXY 5H CYCLOPENTA[D]PYRIMIDINE; ALDEHYDE OXIDASE;

ANALYTIC METHOD; ANIMAL CELL; ARTICLE; CATALYSIS; CONTROLLED STUDY; DIMERIZATION; DRUG METABOLISM; ENZYME ACTIVITY; LIVER CYTOSOL; MALE; NONHUMAN; OXIDATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; RAT; RAT STRAIN; WESTERN BLOTTING;

ALDEHYDE OXIDASE; ANIMALS; DIMERIZATION; MALE; RATS; RATS, INBRED F344; RATS, INBRED LEW; RATS, INBRED WKY; RATS, SPRAGUE-DAWLEY; RATS, WISTAR;

RATTUS;

EID: 34447306002     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250701397713     Document Type: Article

References (24)

1. Beedham C. 1985. Molybdenum hydroxylases as drug-metabolizing enzymes. Drug Metabolism Reviews 16:119-156.
2. Beedham C. 1987. Molybdenum hydroxylases: Biological distribution and substrate-inhibitor specificity. Progress in Medicinal Chemistry 24:85-121.
3. Beedham C. 1997. The role of non-P450 enzymes in drug oxidation. Pharmacy World Science 19:255-263.
4. Beedham C. 2002. Molybdenum hydroxylase. In: C. Ioannides, editor. Enzyme systems that metabolise drug and other xenobiotics. London: Wiley.
5. Beedham C, Al-Tayib Y, Smith JA. 1992. The role of guinea pig and rabbit hepatic aldehyde oxidase in the oxidative in vitro metabolism of cinchona alkaloids. Drug Metabolism and Disposition 20:889-895.
6. Beedham C, Miceli JJ, Obach S. 2003. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. Journal of Clinical Psychopharmacology 23:229-232.
7. Bray RC. 1975. Molybdenum iron-sulfur flavin hydroxylases and related enzymes. In: Boyer PD, editor. The enzymes. 3rd ed. Vol. 12. London: Academic Press.
8. Hoshino K, Itoh K, Masubuohi A, Adachi M, Watanabe N, Kosaka T, Tanaka Y. 2007. Cloning, expression, and characterization of male Cynomolgus monkey liver aldehyde oxidase. Xenobiotica: In press.
9. Itoh K, Yamamura M, Muramatsu S, Hoshino K, Masubuchi A, Sasaki T, Tanaka Y. 2005. Stereospecific oxidation of (S)-enantiomer of RS-8359, a selective and reversible MAO-A inhibitor, by aldehyde oxidase. Xenobiotica 35:561-573.
10. Itoh K, Yamamura M, Takasaki W, Sasaki T, Masubuchi A, Tanaka Y. 2006. Species differences in enantioselective 2-oxidation of RS-8359, a selective and reversible MAO-A inhibitor, and cinchona alkaloids by aldehyde oxidase. Biopharmaceutics and Drug Disposition 27:133-139.
11. Jordan CGM, Rashidi MR, Laljee H, Clarke SE, Brown JE, Beedham C. 1999. Aldehyde oxidase-catalyzed oxidation of methotrexate in the liver of guinea pig, rabbit and man. Journal of Pharmacy and Pharmacology 51:411-418.
12. Kitamura S, Sugihara K, Nakatani K, Ohta S, O'Hara T, Nimomiya S, Green CE, Tyson CA. 1999a. Variation of hepatic methotrexate 7-hydroxylase activity in animals and humans. UBMB Life 48:607-611.
13. Kitamura S, Nakatani K, Sugihara K, Ohta S. 1999b. Strain differences of the ability to hydroxylate methotrexate in rats. Comparative Biochemistry and Physiology Part C 122:331-336.
14. Kitamura S, Sugihara K, Ohta S. 2006. Drug-metabolizing ability of molybdenum hydroxylase. Drug Metabolism Pharmacokinetics 21:83-98.
15. Kunieda T, Kobayashi E, Tachibana M, Ikadai H. 1999. A genetic linkage map of rat chromosome 9 with a new locus for variant activity of liver aldehyde oxidase. Experimental Animals 48:43-45.
16. Miura H, Naoi M, Nakahara D, Ohta T, Nagatsu T. 1993. Changes in monoamine levels in mouse brain elicited by forced-swimming stress, and the protective effect of a new monoamine oxidase inhibitor, RS-8359. Journal of Neural Transmission 94:175-187.
17. Plenker A, Puchler K, Volz HP. 1997. The effects of RS-8359 on cardiovascular function in healthy subjects and depressed patients. International Clinical Psychopharmacology 12:S25-S29.
18. Prakash C, Kamel A, Gummerus J, Wilner K. 1997. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metabolism and Disposition 25:863-875.
19. Puchler K, Schaffler K, Plenker A. 1997. The comparative effects of single and multiple doses of RS-8359, moclobemide and placebo on psychomotor function in healthy subjects. International Clinical Psychopharmacology 12:S17-S23.
20. Rashidi MR, Smith JA, Clarke SE, Beedham C. 1997. In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit and rat liver. Drug Metabolism and Disposition 25:805-813.
21. Sasaki T, Masubuchi A, Yamamura M, Watanabe N, Hiratsuka M, Mizugaki M, Itoh K, Tanaka Y. 2006. Rat strain differences in Stereospecific 2-oxidation of RS-8359, a reversible and selective MAO-A inhibitor, by aldehyde oxidase. Biopharmaceutics and Drug Disposition 27:247-255.
22. Sugihara K, Kitamura S, Tatsumi K. 1995. Strain differences of liver aldehyde oxidase activity in rat. Biochemistry and Molecular Biology International 41:1153-1160.
23. Takasaki W, Yamamura M, Nozaki A, Nitanai T, Sasahara K, Itoh K, Tanaka Y. 2005. Stereoselective pharmacokinetics of RS-8359, a selective and reversible MAO-A inhibitor, by species-dependent drug metabolizing enzymes. Chirality 17:135-141.
24. Yokoyama T, Karube T, Iwata N. 1989. Comparative studies of the effects of RS-8359 and safrazine on monoamine oxidase in vitro and in vivo in mouse brain. Journal of Pharmacy and Pharmacology 41:32-36.